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INTRODUCTION
The brain–body interface comprises many physiological 
interactions which can go awry in disease states. 
Under conditions of normal homeostasis, brain–body 
associations are frequently characterized as interactions 
between the human nervous system and the 
cardiovascular, respiratory, endocrinological, and 
gastrointestinal systems.
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Abstract
Background: Brain–body associations are essential in influencing outcome in 
patients with ruptured brain aneurysms. Thus far, there is scarce literature on such 
important relationships.
Methods: The multicenter Tirilazad database (3551 patients) was used to create 
this clinical outcome prediction model in order to elucidate significant brain–body 
associations. Traditional binary logistic regression models were used.
Results: Binary logistic regression main effects model included four statistically 
significant single prognostic variables, namely, neurological grade, age, stroke, 
and time to surgery. Logistic regression models demonstrated the significance of 
hypertension and liver disease in development of brain swelling, as well as the 
negative consequences of seizures in patients with a history of myocardial infarction 
and post‑admission fever worsening neurological outcome.
Conclusions: Using the aforementioned results generated from binary logistic 
regression models, we can identify potential patients who are in the high risk 
group of neurological deterioration. Specific therapies can be tailored to prevent 
these detriments, including treatment of hypertension, seizures, early detection 
and treatment of myocardial infarction, and prevention of hepatic encephalopathy.
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The brain–body interface
Cardiovascular‑nervous system associations
Direct and indirect projections of the autonomic 
nervous system control the cardiovascular system. 
These projections act via the parabrachial nucleus 
of the midbrain and pons. The parabrachial nucleus 
is a relay station that transmits signals between the 
cerebral cortex (especially limbic cortex), amygdala, 
hypothalamic paraventricular nucleus, vasomotor area of 
the lower brainstem (including the ventrolateral medulla, 
medullary raphe, nucleus of the solitary tract), and the 
thoracolumbar interomediolateral gray column of the 
spinal cord.[2,3,4,11]
The autonomic nervous system mediates the heart rate 
(chronotrophy), rate of nervous impulse transmission 
through the cardiac conductive tissue (dromotropy), and 
force of contraction (inotropy). Blood vessel diameter 
and tone are also mediated via the autonomic nervous 
system.
Counter‑regulatory feedback with the sympathetic 
nervous system predominates. An example of such 
counter‑regulatory feedback is the Cushing reflex. 
Increase in intracranial pressure from disease states, such 
as intracerebral hemorrhage, leads to decreased levels of 
oxygen and increased local levels of hydrogen ions and 
carbon dioxide around the vasomotor regions of the 
lower brainstem secondary to anaerobic metabolism. As 
a counter‑regulatory measure, the systemic blood pressure 
is elevated in an attempt to increase blood flow to the 
brain. With this increase in blood pressure, heart rate is 
reflexively decreased via the arterial baroreceptors.[27,28,46,48]
Other factors also affect the amount of autonomic 
nervous output from the vasomotor regions of the 
brainstem, including
1. Blood oxygen level,
2. Blood carbon dioxide level,
3. Pain stimulus,
4. Chemoreceptors and baroreceptors in the carotid, 
pulmonary, and aortic vessels sense corresponding 
changes,
5. Nerve impulse feedback from the lungs secondary to 
lung inflation and deflation, and
6. Regulatory signals between the cerebral cortex and 
brainstem.
Respiratory‑nervous system associations
Pacemaker cells in the medulla are responsible for 
the autonomic control of respiration. Their rhythmic 
discharges are modified by pneumotaxic neurons in the 
pons, as well as limbic and hypothalamic lesions.[3,4,11] 
Other contributions include:
1. Impulses from afferent pulmonary vagal fibers with 
lung inflation and deflation,
2. Spinal reflexes from cervical and thoracic spinal cord 
to the diaphragm and intercostal muscles,
3. Changes in the cerebrospinal fluid concentrations 
of carbon dioxide and hydrogen ions sensed by 
medullary chemoreceptors, and
4. Changes in oxygen tension sensed by baroreceptors 
in the aorta, cardiac atrium, and ventricle, as well as 
pulmonary arteries.
Endocrinological‑nervous system associations
The hypothalamic‑pituitary axis regulates the key aspects 
of homeostasis, temperature control, and endocrinological 
functions. This system integrates inputs from both the 
limbic system and brainstem in order to modulate both 
emotional and instinctual reactions to changes in the 
internal milieu.[2,3,11,43]
Gastrointestinal‑nervous system associations
The gastrointestinal autonomic nervous system regulates 
the central nervous system inputs to the enteric system 
regarding gut motility and secretory functions. It works in 
conjunction with local paracrine pathways.[2,3,11]
Aneurysmal subarachnoid hemorrhage and alterations in 
brain–body associations
Patients with ruptured brain aneurysms and associated 
subarachnoid hemorrhage (SAH) have a mortality rate 
of at least 45% in the first month after rupture.[32,33] 
Neurological damage can be from the primary injury of 
the aneurysm rupture itself and a number of secondary 
injurious processes that can further worsen the affected 
individual’s neurological state. These secondary 
processes can be related to the nervous system, such as 
rebleeding from the ruptured aneurysm, brain swelling, 
occurrence of a delayed second stroke, brain blood 
vessel vasospasm leading to strokes, seizures, and over 
accumulation of brain spinal fluid causing hydrocephalus. 
In addition, other body organ systems can be affected, 
such as myocardial infarction and over accumulation 
of fluid in lungs causing pulmonary edema. Together, 
these processes can lead to long‑term disability. Types 
of disability include physical, neurocognitive, and 
psychological impairment. Table 1 summarizes alterations 
in physiological interactions in the brain–body interface.
The Tirilazad database
Tirilazad was a 21‑aminosteroid compound produced by 
Pharmacia and Upjohn, Kalamazoo, Michigan. It was 
originally investigated as a free radical scavenger for the 
potential treatment of cerebral vasospasm. Between 1991 
and 1997, 3551 patients from 171 centers in 22 countries 
in North America, Europe, Australia, New Zealand, and 
Africa participated in five randomized, double‑blind, 
placebo‑controlled trials of Tirilazad.[12,13,21,25,26]
Included patients were adults with evidence of aneurysmal 
SAH. The patients received either placebo or active 
agent (in intravenous doses of 0.6, 2.6, or 15 mg/kg/day 
depending on the trial) from the third to tenth day after 
onset of SAH. Excluded patients were:
SNI: Neurovascular 2016, Vol 7: Suppl 18 - A Supplement to Surgical Neurology International
S529
1. Those with traumatic SAH,
2. Those with infectious mycotic aneurysms,
3. Severe underlying medical illnesses including serious 
cardiovascular diseases, such as myocardial infarction 
within the previous 6 months, uncontrolled 
hypertension, serious cardiac arrthymias, or 
congestive heart failure,
4. Pregnant or lactating patients,
5. Patients taking corticosteroids or calcium channel 
blockers other than nimodipine,
6. Known intolerance to calcium channel blockers, and
7. Patients whose aneurysms were treated with Gulielmi 
or other detachable coils.
Patients in the placebo and treatment arms were otherwise 
treated similarly. Over 85% of patients underwent surgical 
clipping, and half of them were operated within the first 
48 hours. Baseline demographics in both the arms were 
balanced in terms of sex, age, number of pre‑existing 
medical conditions, mean time to treatment, mean 
admission systolic blood pressure, admission neurological 
grade, ruptured aneurysm location, amount of blood 
visualized on admission computed tomography (CT) 
scan (measured by the Fisher scale taking into account 
thickness of the blood clot with or without intraventricular 
component). The potential confounder of patient sex 
was accounted for in statistical analysis in the North 
American Tirilazad trial where fewer female patients were 
randomized to the treatment arm.[13] The percentages of 
patients experiencing neurological and systemic disabilities 
were similar in different treatment groups.[12,13,21,25,26]
Only 1% of patients were lost to follow‑up. The primary 
outcome measure was the patient’s Glasgow Outcome 
Score (GOS) at 3 months after aneurysmal rupture. GOS 
is a 5‑point scale, defined as: 5 – good recovery with 
normal life activities despite minor deficits, 4 – moderate 
disability being disabled but independent, 3 – severe 
disability being conscious but dependent, 2 – persistent 
vegetative state, and 1 – death.[19]
Two systematic reviews involving the five Tirilazad trials 
found no substantial heterogeneity among these trials, 
and no significant differences between treatment and 
placebo arms, or among patients who were administered 
different dosages of Tirilazad regarding the number 
of patients who died, the number of adverse events, or 
neurological outcome at 3 months follow‑up.[17,49]
Objectives
Using data from the placebo and Tirilazad arms of the 
five clinical trials, we aim to create a clinical outcome 
prediction model using binary logistic regression and 
investigate the potential factors for outcome prediction 
in patients with ruptured brain aneurysms. In particular, 
we assess the interaction of potential factors and explore 
the role for possible associations between the brain and 
other organ systems.
MATERIALS AND METHODS
The Tirilazad database was used to investigate the 
potential factors for outcome prediction in aneurysmal 
SAH and to assess interactions of factors between the 
brain and other organ systems.
Table 2 summarizes the independent variables recorded 
in the Tirilazad database.
The dependent variable used for statistical analysis is 
the dichotomized GOS at three months, that is, good 
Table 1: Brain-body interface under normal homeostasis and after aneurysmal subarachnoid hemorrhage
Brain-body interface under normal homeostasis Alterations in aneurysmal subarachnoid hemorrhage
Cardiovascular system
‑Autonomic nervous control of cardiovascular system:
1. Counter‑regulatory feedback with sympathetic nervous 
system, and
2. Primary relay station being vasomotor regions of the 
lower brainstem
Cardiovascular system dysfunction
‑Altered autonomic nervous control of cardiovascular system:
1. Sympathetic nervous system activation,
2. Blood pressure changes sensed by carotid sinus baroreceptors, and
3. Blood around lower brainstem triggers catecholamine release from thoracic 
paravertebral chain
Pulmonary system
‑Automatic control of respiration by lower brainstem’s 
pacemaker cells with additional modifications by:
1. Brainstem chemoreceptors and vascular 
baroreceptors,
2. Brain (limbic, hypothalamic, and brainstem) inputs and 
spinal (cervical and thoracic cord) reflexes, and
3. Pulmonary local volume and vascular controls
Pulmonary system dysfunction
‑Altered autonomic control of respiration with sympathetic surge:
1. Blood oxygen, carbon dioxide, and pH levels change and sensed by 
chemoreceptors and baroreceptors,
2. Altered brain and spinal inputs trigger hyperventilation and ataxic breathing 
patterns, and
3. Increased pulmonary vascular permeability and venous pressures leading 
to hydrostatic pulmonary edema.
Endocrine system
‑Hypothalamic‑pituitary axis coordinates key aspects of 
homeostasis
1. Counter‑regulatory feedback with target end organs 
including the adrenal glands
Endocrinological system dysfunction
‑Altered hypothalamic‑pituitary axis:
1. Sodium and water imbalance triggered by early altered levels of natriuretic 
peptides and later compensation by the renin‑angiotensin‑aldosterone system
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or poor outcome. Good outcome represents functional 
independence (GOS 5 or 4). Poor outcome represents 
functional dependence (GOS 3), persistent vegetative 
state (GOS 2) or death (GOS 1).[16]
Table 3 summarizes neurologic and systemic factors, 
as well as a priori hypotheses investigated possible 
interactions between brain and other organ systems.
Using IBM’s the Statistical Package for the Social Sciences 
version 19.0TM, independent variables were entered into 
univariate models in which Chi‑square analyses were 
performed to investigate associations with poor outcome. 
Two‑way interaction terms that included neurologic and 
systemic prognostic factors were examined [Table 3]. 
Variables that reached a probability of 0.10 were then 
entered into a multivariable binary logistic regression 
model. Variables that reached P ≤ 0.05 were deemed 
significant. For Hosmer and Lemeshow test for goodness 
of fit of the model, P ≥ 0.05 was deemed significant.[15,44] 
Multivariable analyses had at least 10 participants per 
independent variable, which is the minimum number 
required for a stable multivariable model using logistic 
regression.[15,44]
In the multivariable logistic regression model, the 
following diagnostics were performed:
1. Correlation matrix to rule out multicollinearity 
among predictor variables,
2. Hosmer and Lemeshow test to ensure good data fit 
to model and model calibration,
3. C statistic and classification to examine model 
discrimination, and
4. Split‑sample analysis (70% training and 30% testing) 
to examine model generalizability.
RESULTS
Patient selection and participation in the Tirilazad trials 
are summarized in Figure 1. Characteristics of the study 
patient population are summarized in Table 4.
Correlated matrix of the included independent variables 
was examined to ensure that there were no correlated 
variables. Variables and interaction terms that reached a 
probability of 0.10 were entered into the multivariable 
binary logistic regression model. These variables and 
interaction terms are summarized in Table 5. Significant 
single prognostic variables and interaction terms were 
entered into a multivariable binary logistic regression 
model. The final model includes significant single 
prognostic variables and interaction terms summarized in 
Table 6.
Table 2: Independent variables recorded in the Tirilazad database
Demographic sactors Neurological factors Systemic factors
1. Sex Non‑treatment related factors
2. Age (years) 1. Hospital admission neurological grade (Hunt and Hess) 1. Systolic blood pressure (mmHg)
3. Patient’s weight (kg) 1 ‑ Asymptomatic 2. Diastolic blood pressure (mmHg)
2 ‑ Headaches, cranial nerve palsy 3. Temperature on admission (degree Celsius)
3 ‑ Mild focal deficit, confusion 4. Occurrence of fever one week after hospital admission
4 ‑ Stupor, moderate to severe hemiparesis 5. History of hypertension
5 ‑ Deep coma, moribund 6. History of angina
2. Aneurysm size (≤12 mm or >12 mm) 7. History of myocardial infarction
3. Presence of angiographic vasospasm on hospital admission 8. History of diabetes mellitus
4. Presence of intraventricular hemorrhage 9. History of hepatic disease
5. Presence of intracerebral hemorrhage 10. History of thyroid disease
6. Location of aneurysm (anterior or posterior circulation) 11. Development of pulmonary edema
7. Thickness of subarachnoid hemorrhage (≤1 mm or >1 mm)
8. Prior episode of subarachnoid hemorrhage
9. History of migraines
10. Presence of hydrocephalus
11. Development of cerebral edema
12. Occurrence of stroke post admission
13. Development of vasospasm during course of treatment
14. Seizures requiring antiepileptic medications
Treatment related factors
1. Time to surgical treatment (hours)
2. Treatment arm
3. Severe vasospasm requiring balloon angioplasty
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Table 3: A priori hypotheses for brain-body interactions and their rationale
Systemic factors and rationale for investigating brain–body interactions
Age
Age, along with clinical pre‑operative grade and CT findings are associated with poor neurological outcome in aneurysmal SAH.[14,42] Both 
cerebral and systemic atherosclerotic changes occur as one ages
hypertension
Hypertension is associated with poor neurological outcome in aneurysmal SAH as it predisposes to hemodynamic related structural damage in 
cerebral blood vessels, including endothelial damage and decreased elasticity of blood vessel wall.[1,29,30]
History of diabetes
Diabetes and poor glycemic control are associated with symptomatic vasospasm.[10] Insulin resistance is associated with dysfunction of 
vascular resistance vessels, including endothelial hypertrophy and altered contractile properties.
History of liver disease
Hepatic dysfunction is associated with poor clinical grade at hospital admission. During the course of treatment, liver dysfunction is observed in 
up to 25% of aneurysmal SAH patients.[4]
History of thyroid disease
Sick euthyroid syndrome may be observed in aneurysmal SAH patients with previously normal functioning thyroid gland. During acute physiological 
stress, these patients may have decreased amounts of thyroid hormone, and inhibition of thyroxine production by elevated cortisol levels.[7,34]
Occurrence of fever at 1 week post admission
Fevers are associated with increased cerebral metabolic rates. Even one episode of fever after aneurysmal SAH can be associated with poor 
outcome.[45]
History of myocardial infarction
Patients with a history of myocardial infarction are prone to troponin elevations and decompensated heart failure after SAH.[22] Those with 
elevated troponin levels and heart failure are more likely to have significant morbidity and mortality
Neurologic factors and specific a priori hypotheses
Neurological grade
I will investigate the degree by which admission neurological grade influences clinical outcome if the aneurysmal SAH patients also have the 
following conditions, as they are prone to complications arising from them:
(1) Increasing age (age and neurological grade)
(2) Hypertension (hypertension and neurological grade)
(3) Diabetes (diabetes and neurological grade)
(4) Liver disease (liver disease and neurological grade)
(5) Thyroid disease (thyroid disease and neurological grade)
(6) Fever (fever and neurological grade), and
(7) Myocardial infarction (myocardial infarction and neurological grade)
Occurrence of stroke post admission
I hypothesize that aneurysmal SAH patients who experience post admission stroke may have poor clinical outcome if they also have the 
following conditions:
(1) Increasing age (age and stroke)
(2) Hypertension (hypertension and stroke)
(3) Diabetes (diabetes and stroke)
(4) Liver disease (liver disease and stroke)
(5) Fever (fever and stroke), and
(6) Myocardial infarction (myocardial infarction and stroke)
Aneurysmal SAH patients with post admission stroke and the aforementioned systemic conditions are predisposed to related complications 
including rebleeding, seizures, cerebral edema, delayed stroke, and vasospasm
Development of vasospasm during course of treatment
Aneurysmal SAH patients who experience vasospasm may be predisposed to poor clinical outcome as they are more likely to experience 
complications including delayed stroke and rebleeding if they concomitantly have the following conditions:
(1) Hypertension (hypertension and vasospasm)
(2) Diabetes (diabetes and vasospasm)
(3) Liver disease (liver disease and vasospasm)
(4) Fever (fever and vasospasm), and
(5) Myocardial infarction (myocardial infarction and vasospasm)
Seizures requiring antiepileptic medications
Contd...
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The multivariable binary logistic regression model found 
four statistically significant single prognostic variables, 
namely, admission neurological grade, age, time to 
surgery and post‑admission stroke, and four significant 
interaction terms. These observations are listed as 
follows:
1. The odds of poor outcome associated with one unit 
increase in neurological grade is increased by a factor 
of 2.06,
2. The odds of poor outcome associated with one unit 
(every 5 years) increase in age is increased by a factor 
of 1.28,
3. The odds of poor outcome associated with one unit 
(every hour) increase in time to surgery is increased 
by a factor of 1.01, and
4. The odds of poor outcome is increased by a factor 
of 4.0 when the aneurysmal SAH patient experiences 
post‑hospital admission stroke.
The multivariable binary logistic regression model also 
found four statistically significant interaction terms. 
These observations are listed as follows:
1. The odds of poor outcome is increased by a factor of 
2.39 when the aneurysmal SAH patient experiences 
fever 1 week post‑hospital admission and seizures,
Table 3: Contd...
I hypothesize that aneurysmal SAH patients with the following systemic conditions who experience seizures may be predisposed to poor clinical 
outcome arising from complications including status epilepticus, cerebral edema, vasospasm, and delayed stroke:
(1) Increasing age (age and seizures)
(2) Hypertension (hypertension and seizures)
(3) Diabetes (diabetes and seizures)
(4) Liver disease (liver disease and seizures)
(5) Fever (fever and seizures), and
(6) Myocardial infarction (myocardial infarction and seizures)
Aneurysm size
Aneurysmal SAH patients with hypertension (hypertension and aneurysm size) and myocardial infarction (myocardial infarction and aneurysm 
size) may experience rebleeding complicating their clinical course leading to poor clinical outcome.
Presence of intraventricular hemorrhage
I hypothesize that aneurysmal SAH patients with intraventricular hemorrhage and the following systemic conditions are more likely to 
experience complications including hydrocephalus and rebleeding which may lead to poor clinical outcome:
(1) Increasing age (age and intraventricular hemorrhage)
(2) Hypertension (hypertension and intraventricular hemorrhage)
(3) Diabetes (diabetes and intraventricular hemorrhage)
(4) Liver disease (liver disease and intraventricular hemorrhage)
(5) Fever (fever and intraventricular hemorrhage), and
(6) Myocardial infarction (myocardial infarction and intraventricular hemorrhage)
Presence of intracerebral hemorrhage
Aneurysmal SAH patients with post admission intracerebral hemorrhage are prone to poor clinical outcome arising from complications including 
rebleeding, seizures, cerebral edema, and vasospasm, if they also have the following conditions:
(1) Increasing age (age and intracerebral hemorrhage)
(2) Hypertension (hypertension and intracerebral hemorrhage)
(3) Diabetes (diabetes and intracerebral hemorrhage)
(4) Liver disease (liver disease and intracerebral hemorrhage)
(5) Fever (fever and intracerebral hemorrhage), and
(6) Myocardial infarction (myocardial infarction and intracerebral hemorrhage)
Development of cerebral edema
I hypothesize that aneurysmal SAH patients who develop post rupture cerebral edema and, concomitantly, have the following conditions, may be 
prone to poor clinical outcome:
(1) Increasing age (age and cerebral edema)
(2) Hypertension (hypertension and cerebral edema)
(3) Diabetes (diabetes and cerebral edema)
(4) Liver disease (liver disease and cerebral edema)
(5) Fever (fever and cerebral edema), and
(6) Myocardial infarction (myocardial infarction and cerebral edema)
These patients may experience seizures and delayed stroke as possible related complications
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2. The odds of poor outcome is increased by a factor of 
5.47 when the aneurysmal SAH patient with history 
of hepatic disease develops cerebral edema,
3. The odds of poor outcome is increased by a factor of 
2.66 when the aneurysmal SAH patient with history 
of hypertension develops cerebral edema, and
4. The odds of poor outcome is increased by a factor of 
3.05 when the aneurysmal SAH patient with history 
of myocardial infarction develops seizures.
The Omnibus Tests of Model Coefficients indicated 
that this model was statistically significant 
(Chi‑square = 887.90, P < 0.01). This model showed 
a large significant reduction in −2 log likelihood 
(−2 LL from 2240 to 1699, P < 0.01). Nagelkerke R2 
statistic indicated that approximately 47% of the variance 
in poor neurologic outcome could be predicted from the 
combination of the significant terms. In terms of model 
discrimination [Figure 2], the c statistic was 0.87 (95% 
confidence interval 0.86–0.89).
Classification table indicated that 84% of subject 
outcomes were predicted correctly. In terms of model 
calibration, the Hosmer and Lemeshow test showed a 
Chi‑square of 11.38, P = 0.18, suggesting that the model 
appeared to fit the data well. Generalizability of model 
findings was supported by split sample validation (70% 
training and 30% testing). The following are the findings:
1. No multicollinearity (standard errors for beta 
coefficients less than 2),
2. Individual relationship Wald statistic significance less 
than alpha level of 0.05, and
3. Classification accuracy rate for training sample 
was 84.5%, whereas classification accuracy rate 
for testing sample was 82.5%, both satisfying 
minimum requirement for holdout sample 
(0.9 × 84.5% = 76%), and
4. Classification accuracy (84.5%) was 1.025 times 
chance accuracy (82.5%).
DISCUSSION
There has been scarce literature attempting to characterize 
complex brain–body associations in patients with 
ruptured brain aneurysms. This analysis included both 
non‑treatment and treatment related prognostic factors, 
as well as two‑way interactions, which described clinically 
relevant brain–body associations in aneurysmal SAH.
Figure 1: Patient selection and participation in the Tirilazad trials
Table 4: Characteristics of the study patient population
Characteristic (n=3551) Statistic
Demographic factors
Mean age (years) 51.7±13.2
Female sex (percent) 2933 (82.6)
Patient weight (kilogram) 69.5±15.0
Neurological factors
Non‑treatment related
Hospital admission neurological grade
Hunt and Hess Grade 1 (%) 1289 (36.3)
Hunt and Hess Grade 2 (%) 1045 (29.4)
Hunt and Hess Grade 3 (%) 417 (11.7)
Hunt and Hess Grade 4 (%) 355 (10.0)
Hunt and Hess Grade 5 (%) 445 (12.5)
Aneurysm size ≤12 mm (%) 2594 (73.0)
Presence of admission angiographic vasospasm (%) 412 (11.6)
Presence of intraventricular hemorrhage (%) 1588 (44.7)
Presence of intracerebral hematoma (%) 818 (23.0)
Posterior circulation location of aneurysm (%) 498 (14.0)
Subarachnoid hemorrhage thickness ≤1 mm (%) 1214 (34.2)
Prior episode of SAH (%) 340 (9.6)
History of migraines (%) 915 (25.8)
Presence of hydrocephalus (%) 1497 (42.2)
Development of cerebral edema (%) 381 (10.7)
Occurrence of post admission stroke (%) 979 (27.6)
Development of vasospasm during treatment (%) 1059 (29.8)
Treatment related
Seizures requiring antiepileptic medications (%) 2313 (65.1)
Mean time to surgical treatment (hours) 0.9±1.9
Treatment arm receiving Tirilazad (%) 2173 (61.2)
Severe vasospasm needing balloon angioplasty (%) 158 (4.4)
Systemic factors
Mean systolic blood pressure (mmHg) 141.2±24.7
Mean diastolic blood pressure (mmHg) 76.6±15.2
Mean temperature on admission (degree Celsius) 37.0±0.9
Occurrence of fever one week after admission (%) 1753 (49.4)
History of hypertension (%) 1217 (34.3)
History of angina (%) 129 (3.6)
History of myocardial infarction (%) 87 (2.5)
History of diabetes mellitus (%) 155 (4.4)
History of hepatic disease (%) 127 (3.6)
History of thyroid disease (%) 291 (8.2)
Development of pulmonary edema (%) 313 (8.8)
Data are presented as the mean±standard deviation, or as the number of patients (%)
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The main effects logistic regression model confirmed the 
significance of neurological grade, age, stroke, and time 
to surgery in outcome prognosis in aneurysmal SAH.
This study also demonstrates that the odds of poor 
neurological outcome is increased by a factor of 4 in 
aneurysmal SAH patients who develop post‑admission 
strokes (OR: 4.03, 95% CI: 2.11–7.69, P < 0.01). With 
modern modalities of routine cerebral surveillance 
imaging over the course of treatment, up to half of 
aneurysmal SAH patients have observed non‑resolving 
hypodensities and persistent areas of cerebral perfusion 
deficits, which is consistent with stroke. It is increasingly 
recognized that cerebral infarction after aneurysmal 
SAH may occur early after aneurysmal rupture or in a 
delayed manner. Factors associated with development 
of cerebral infarction include admission neurological 
status, treatment related complications, and occurrence 
of symptomatic vasospasm.[23,41] Secondary injury 
cascade events predisposing aneurysmal SAH patients 
to post admissions strokes include: (1) Microthrombi 
formation, (2) cortical spreading depression, 
(3) microvascular constriction, (4) proliferation of 
pro‑inflammatory cascade, (5) presence of blood‑brain 
barrier disruption, and (6) inadequate collateral 
circulations.
In addition, this study found that timing to surgical 
treatment of ruptured aneurysms is significant in 
determining neurological outcome. This is supported 
from the observation that shorter time interval to 
treatment is associated with reduction in aneurysmal 
rebleeding rates.[38]
We also make the observation that development of 
cerebral edema, in the context of history of hypertension 
and liver disease, has significant impact on neurologic 
outcome deterioration in aneurysmal SAH.
By itself, development of cerebral edema may predispose 
the aneurysmal SAH to poor neurological outcome (OR: 
1.84, 95% CI: 1.29–2.62, P < 0.01, univariate analysis). 
Figure 2: ROC curve to analyze logistic regression model 
discrimination. Output figure generated by IBM SPSS Version 19.0 
(Armonk NY)
Table 5: Univariate analysis main effects variables and 
interaction terms
Variable terms Odds 
ratios
95% confidence 
intervals
P value
Main effects variables
Neurological grade 2.06 1.82‑2.31 <0.01
Age (years) 1.05 1.04‑1.07 <0.01
Time to surgery (hours) 1.00 1.00‑1.01 0.03
Fever on day 8 1.94 1.51‑2.49 <0.01
Aneurysm size 1.37 1.04‑1.80 0.02
Admission vasospasm 1.54 1.04‑2.30 0.03
Intraventricular hemorrhage 1.33 1.02‑1.73 0.04
Brain Edema 1.84 1.29‑2.62 <0.01
Intracerebral hemorrhage 1.39 1.04‑1.87 0.03
History of hypertension 1.37 1.05‑1.79 0.02
History of myocardial infarction 2.07 1.01‑4.27 0.06
Post admission stroke 6.35 4.90‑8.24 <0.01
Previous subarachnoid hemorrhage 1.60 1.07‑2.39 0.02
Aneurysm location 1.72 1.18‑2.51 0.01
Vasospasm 1.58 1.21‑2.06 <0.01
Seizures 1.68 1.28‑2.21 <0.01
Interaction terms
Fever on day 8 by aneurysm size 2.63 2.10‑3.31 <0.01
Fever on day 8 by intraventricular 
hemorrhage
3.21 2.68‑3.83 <0.01
Fever on day 8 by seizures 2.66 2.24‑3.14 <0.01
Brain edema by hepatic disease 3.50 1.24‑9.86 0.02
Brain edema by history of 
hypertension
4.18 2.96‑5.91 <0.01
Hydrocephalus by hepatic disease 1.82 1.02‑3.23 0.04
History of myocardial infarction 
by subarachnoid hemorrhage 
thickness
2.63 1.53‑4.53 <0.01
History of myocardial infarction 
by seizures
3.35 1.86‑6.05 <0.01
Table 6: Statistically significant terms in the final binary 
logistic regression model
Variable Terms Odds 
ratios
95% confidence 
intervals
P value
Neurological grade 2.06 1.83‑2.32 <0.01
Age (per year) (for every Δ5 years) 1.06
[1.28]
1.05‑1.07
[1.22‑1.42]
<0.01
Time to surgery (hour) 1.01 1.00‑1.02 0.02
Stroke 4.03 2.11‑7.69 <0.01
Seizures by fever on day 8 2.39 1.86‑3.06 <0.01
Brain edema by hepatic disease 5.47 1.13‑26.46 0.03
Brain edema by hypertension 2.66 1.59‑4.45 <0.01
Seizures by myocardial infarction 3.05 1.35‑6.87 0.01
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Further examination of systemic factors revealed that 
aneurysmal SAH patients with a history of hypertension 
and development of cerebral edema have 2.7 fold increased 
odds of poor neurologic outcome (OR: 2.66, 95% CI 
1.59–4.45, P < 0.01). Patients with a history of hypertension 
are more prone to defective cerebral autoregulation. When 
cerebral dysautoregulation is present after aneurysmal 
SAH, brain engorgement can occur as plasma proteins leak 
from capillaries with increased permeability. Extracellular 
vasogenic edema may follow as a result of increased 
hydrostatic pressures, with predilection for posterior cerebral 
circulation territories.[39,40] It is important, therefore, to 
recognize that chronic hypertensive patients have altered 
elevated blood pressure ranges for autoregulation. It is also 
essential to monitor the development of cerebral edema in 
these patients.
This study also makes the novel observation that 
development of cerebral edema in aneurysmal SAH 
patients with a history of liver dysfunction markedly 
increases likelihood for poor outcome (OR: 5.47, 95% 
CI: 1.13–26.46, P = 0.03). Similar to patients with 
hypertensive history, patients with chronic liver disease 
have been shown to have altered cerebral autoregulation 
and cerebral blood flow with decreased cerebral blood 
flow in the anterior cingulum and increased blood flow in 
the basal ganglia and occipital lobes at baseline. In acute 
states of ruptured cerebral aneurysms, these patients’ 
blood brain barriers become disrupted with marked 
increased cerebral blood flow secondary to luxuriant 
perfusion, thus, predisposing them to the development of 
vasogenic edema. In addition, cytotoxic osmoregulatory 
mechanisms are involved whereby astrocytes swell 
secondary to the toxic effects of ammonia and glutamate. 
The end result is a vicious cycle of neuronal swelling 
and death, marked increased in cerebral blood flow 
(cerebral hyperemia), and cerebral edema.[5,6,8,37] It is 
important, therefore, to prevent the development of 
hepatic encephalopathy and monitor for cerebral edema 
in aneurysmal SAH patients who have chronic liver 
dysfunction.
Seizures post‑aneurysmal SAH increase mortality. The 
observed incidence of seizures can be as high as 15% 
in the aneurysmal SAH patient population.[45,47] In this 
study, we observed that seizures increase the odds of poor 
outcome by a factor of 1.68 (95% CI: 1.28–2.21, P < 0.01, 
univariate analysis). However, occurrence of seizures in the 
clinical settings of post–admission fever and background 
history of myocardial infarction significantly increases 
morbidity and mortality. The epileptic aneurysmal SAH 
patient who develops post–admission fever is predisposed 
to poor outcome (OR: 2.39, 95% CI: 1.86–3.06, P < 0.01). 
Fevers increase cerebral metabolic rate and can exacerbate 
secondary injury. Early onset fevers can be secondary 
to dysfunction of temperature regulation centers in the 
hypothalamus whereas late onset fevers are more likely 
to be infectious, but can include fevers secondary to 
drugs and pulmonary embolism.[27,28,36,48] Exogenous and 
endogenous pyrogens increase the propensity for fevers 
and seizure development. In febrile states, inflammatory 
cytokines increase neuronal excitability via temperature 
sensitive ion channels leading to an increased likelihood 
of synchronized neuronal activity.[9,20,34,35] Not only is it 
essential to monitor and treat both seizures and fevers 
themselves, it is also important to search for underlying 
etiologies, including infections, pulmonary embolism, 
drug‑drug interactions and delayed strokes which may 
alter seizure thresholds in the febrile aneurysmal SAH 
patient.
Finally, our analysis makes the observation that seizures 
in the setting of history of myocardial infarction increase 
the odds of poor outcome by a factor of 3.05 (95% CI: 
1.35–6.87, P = 0.01). Repetitive autonomic stimulation 
can occur in the actively seizing aneurysmal SAH patient 
in a lock step phenomenon, which can trigger the 
development of cardiac ictal arrthymias.[6,18,29] Continuous 
cardiac sympathetic discharges and cortical epileptiform 
activity can occur in a synchronized time‑locked manner. 
These repetitive synchronized autonomic sympathetic 
discharges lead to cardiac ischemia and structural damage 
to the myocardium.[24] In aneurysmal SAH, patients with 
pre‑existing coronary artery disease and seizures, the 
propensity of cardiac ischemia is increased, along with 
potentially fatal multi‑systemic complications, including 
development of neurogenic pulmonary edema and 
respiratory suppression associated with fatal cardiac tachy 
or bradyarrthymias, or cardiac asystole. Multi‑system 
critical care cardiovascular and respiratory supports, 
therefore, are essential in these epileptic aneurysmal SAH 
patients in order to maximize their chances of survival.
Methodological strengths
Our analyses made use of a large multicenter database 
of aneurysmal SAH patients. Multivariable logistic 
regression model is a robust statistical technique 
applicable to this patient cohort because there were: 
(1) No significant differences in patient outcome 
(benefit or harm) between placebo and treatment 
arms, (2) no substantial heterogeneity among different 
Tirilazad trials, (3) baseline demographics in both 
arms were balanced, (4) patients in both arms were 
treated similarly, with statistical analyses accounting for 
potential confounders, (5) similar percentages of patients 
experiencing neurological and systemic disabilities in 
placebo and different treatment groups, and (6) no 
significant between‑center and between‑country effects 
on patient outcome.[12,13,17,21,25,26,31,49]
In addition, we investigated both single prognostic 
factors and explored brain–body interactions. In so doing, 
several novel observations were found which significantly 
influence clinical outcome in aneurysmal SAH patients. 
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Furthermore, we examined model discrimination, 
calibration and validity.
Limitations
This is a retrospective observational study which 
included heterogeneous clusters of patients from 
different geographical regions. Patients of various genetic 
backgrounds may exhibit different clinical responses 
to treatments such as pharmacokinetic profiles to 
medications. In addition, the Tirilazad database did not 
capture important modifiable variables of behaviours 
including smoking and alcohol consumption. Referral 
bias is also present because these patients were admitted 
to and treated at specialized centers with neurosurgical 
and critical care capabilities.
Future directions
Further studies can be carried out to generalize 
these observations to other aneurysmal SAH patient 
populations, including those undergoing coiling.[32] 
Further delineation can also be carried out to investigate 
the impact of brain interactions with other body 
systems, such as renal system, on neurological outcome 
in aneurysmal SAH patients. In addition, clinical 
prediction models formulated using multivariable 
logistic regression analysis and other techniques, such as 
classification and regression tree analysis, can be adopted 
as clinical prognostication tools, openly accessible to the 
clinician in online downloadable formats and applications.
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